Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis
Part of paid clinical trials in New York, New York.
- Sponsor
- NYU Langone Health
- Study ID
- NCT05020028
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Knee Arthritis
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cannabidiol (CBD) — DRUGPatients will be dispensed enough 25mg cannabidiol (CBD) Orally Disintegrating Tablets (ODT) to take a standard dose of 50mg three times daily for 84 days.
- Placebo — DRUG25mg Placebo ODT looks like the cannabidiol (CBD) Orally Disintegrating Tablets (ODT), but contains no active ingredients.
Study Details
The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.
Key Dates
- Start date
- Jun 22, 2022
- Status verified
- Jun 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: CBD GroupThe first cohort will take two 25mg cannabidiol (total dose: 50mg) Orally Disintegrating Tablets (CBD ODT) three times daily for a maximum dose of 150mg per day.
- Placebo Comparator: Placebo GroupCohort 2 will receive the same instructions, but with the placebo Orally Disintegrating Tablets (ODT) instead.
Primary Outcome Measure
VAS Pain Severity Score [ Time Frame: Day 1 ]
Central Contacts
- Michael J Alaia, MD646-501-7223
- Layne Estes
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | Michael Alaia, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New York, NY
By research site
Related Studies
- Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee ArthroplastyPHASE4 · Not Yet Recruiting · Emory University · Atlanta, Georgia